Peptide Applications

The self-assembly of bioactive peptides has become a research hotspot and a central direction in food science. Its core value lies in the spontaneous formation of ordered nanostructures—such as nanofibers, micelles, and hydrogels—which precisely addresses the industry's key challenges of gastrointestinal degradation and low bioavailability of functional compounds. This opens a new path for the development of precision nutrition foods and the innovative design of functional carriers. However, challenges such as unclear in vivo behavior and unverified safety remain. The following sections will elaborate on the practical value and application potential of peptide self-assembly in the food sector, focusing on its underlying principles, core advantages, application scenarios, and developmental challenges.

Today, we share an important study led by Professor Runhui Liu's team at East China University of Science and Technology, published in Nature Biotechnology. This research addresses the global challenge of limited efficacy in treating systemic fungal infections (especially meningitis) caused by inconsistent in vivodistribution of synergistic antifungal drugs. The team developed a host defense peptide-mimetic self-assembling micelle delivery system. This strategy involves a bifunctional polymer possessing both antifungal activity and self-assembly carrier capability, which efficiently encapsulates amphotericin B (AmB). This enables spatiotemporally consistent co-delivery of both drugs to the infection site. The system significantly reduces AmB toxicity, broadens its therapeutic window, and demonstrates efficacy superior to the clinical gold-standard therapy (AmBisome combined with 5-fluorocytosine) in mouse models of systemic candidiasis and cryptococcal meningitis. It offers a novel solution for tackling drug-resistant fungal infections.

GLP-1 drugs, as a novel class of therapies combining glucose-lowering, weight-loss, and anti-inflammatory effects, have expanded from their initial use in treating type 2 diabetes (T2D) to encompass obesity and various complications. They also show potential value in new indications such as neurodegenerative diseases and substance use disorders, thereby reshaping public health strategies for chronic disease intervention. This article systematically reviews the current application landscape, expansion directions, efficacy variations, safety profile, and future challenges of GLP-1 drugs, providing a comprehensive reference for understanding their clinical value and developmental potential.

Glucagon-like peptide-1 receptor agonists, as a key therapeutic approach for type 2 diabetes and obesity, have demonstrated significant efficacy in lowering blood glucose, promoting weight loss, improving insulin resistance, and exerting anti-inflammatory effects. Beyond their established role in metabolic disease management, their potential impact on cancer risk has become a focus of research. These agents act by activating the GLP-1 receptor or, in some cases, both the GLP-1R and the glucose-dependent insulinotropic polypeptide receptor. They may influence tumorigenesis and progression through both weight-dependent and weight-independent mechanisms. This article synthesizes relevant clinical evidence, mechanisms of action, and the current state of research to provide a core perspective on the potential anticancer properties of GLP-1R agonists.

In the field of biopharmaceuticals, protein and peptide drugs (PPs) hold a pivotal position in treating various diseases such as diabetes and osteoporosis, owing to their well-defined mechanisms of action, high selectivity, and low side effects. However, the traditional parenteral injection route not only causes pain and inconvenience to patients but may also lead to adverse reactions like subcutaneous nodules and infections, significantly impacting medication adherence. The oral route, as the most convenient and patient-preferred non-invasive administration method, can mimic the natural secretion process of proteins to potentially reduce side effects. Nevertheless, the complex physiological environment of the gastrointestinal (GI) tract presents multiple formidable barriers, resulting in extremely low oral bioavailability for PPs, which constitutes a major challenge for the pharmaceutical industry. This article provides a systematic analysis centered on the core obstacles, breakthrough strategies, current clinical application status, existing challenges, and future directions for oral PPs delivery, offering a clear framework for research and development in this field.

Today, we share important research led by Tawfeeq Shekh-Ahmad's team from the Hebrew University of Jerusalem, published in Redox Biology. This study is the first to systematically evaluate the therapeutic potential of the thioredoxin-mimetic peptide TXM-CB3 (CB3) in a temporal lobe epilepsy model. The research found that CB3 can significantly delay epileptogenesis, reduce spontaneous recurrent seizures (SRS) during the chronic phase, and improve epilepsy-associated cognitive dysfunction by modulating key pathways of oxidative stress and neuroinflammation. Notably, CB3 maintained durable antiepileptic effects even after treatment cessation, demonstrating true disease-modifying therapy characteristics. This offers new hope for approximately 30-40% of patients with drug-resistant epilepsy.